Kura Oncology (KURA) Current Assets (2010 - 2026)
Kura Oncology (KURA) posted quarterly Current Assets of $623.8 million for Q1 2026, down 13.87% year-over-year from $724.2 million in Q1 2025, and down 11.98% quarter-over-quarter from $708.7 million in Q4 2025.
Kura Oncology (KURA) Current Assets (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Current Assets for 17 consecutive years, with $623.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 13.87% year-over-year to $623.8 million; the TTM figure through Mar 2026 stood at $623.8 million (down 13.87% YoY), while the FY2025 annual figure was $708.7 million, down 4.86% from the prior year.
- Current Assets eased to $623.8 million in Q1 2026 per KURA's latest filing, from $708.7 million in the prior quarter.
- Across five years, Current Assets topped out at $744.8 million in Q4 2024 and bottomed at $416.4 million in Q1 2023.
- Historically, Current Assets has averaged $541.6 million across 5 years, with a median of $487.0 million in 2022.
- Annual changes were most pronounced in 2022 — Current Assets retreated 20.5% — and 2024, when it surged 72.22%.
- Kura Oncology's Current Assets stood at $446.4 million in 2022, then dropped by 3.12% to $432.5 million in 2023, then jumped by 72.22% to $744.8 million in 2024, then decreased by 4.86% to $708.7 million in 2025, then fell by 11.98% to $623.8 million in 2026.
- Business Quant data shows KURA's Current Assets at $623.8 million in Q1 2026, $708.7 million in Q4 2025, and $620.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 559.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 559.44 Mn |
| Mar 31, 2026 | 623.78 Mn |
| Dec 31, 2025 | 708.66 Mn |
| Sep 30, 2025 | 620.66 Mn |
| Jun 30, 2025 | 660.08 Mn |
| Mar 31, 2025 | 724.20 Mn |
| Dec 31, 2024 | 744.83 Mn |
| Sep 30, 2024 | 463.19 Mn |
| Jun 30, 2024 | 499.77 Mn |
| Mar 31, 2024 | 537.84 Mn |
| Dec 31, 2023 | 432.48 Mn |
| Sep 30, 2023 | 459.92 Mn |
| Jun 30, 2023 | 485.65 Mn |
| Mar 31, 2023 | 416.45 Mn |
| Dec 31, 2022 | 446.43 Mn |
| Sep 30, 2022 | 436.39 Mn |
| Jun 30, 2022 | 459.79 Mn |
| Mar 31, 2022 | 487.03 Mn |
| Dec 31, 2021 | 522.29 Mn |
| Sep 30, 2021 | 548.91 Mn |